Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment.
Publication/Presentation Date
3-1-2018
Abstract
Bevacizumab failure is a major clinical problem in the management of high grade gliomas (HGG), with a median overall survival (OS) of < 4 months. This study evaluated the feasibility and efficacy of fractionated stereotactic re-irradiation (FSRT) for patients progressed after Bevacizumab treatment. Retrospective review was conducted of 36 patients treated with FSRT after progression on bevacizumab. FSRT was most commonly delivered in 3.5 Gy fractions to a total dose of 35 Gy. Survival from initial diagnosis, as well as from recurrence and re-irradiation, were utilized as study endpoints. Univariate and multivariate analysis was performed. The median time from initial bevacizumab treatment to FSRT was 8.5 months. The median plan target volume for FSRT was 27.5 cc. The median OS from FSRT was 4.8 months. FSRT treatment was well tolerated with no grade 3 or higher toxicity. Favorable outcomes were observed in patients with recurrent HGG who received salvage FSRT after bevacizumab failure. The treatment was well tolerated. Prospective study is warranted to further evaluate the efficacy of salvage FSRT for selected patients with recurrent HGG amenable to FSRT, who had failed bevacizumab treatment.
Volume
137
Issue
1
First Page
171
Last Page
177
ISSN
1573-7373
Published In/Presented At
Shi, W., Blomain, E. S., Siglin, J., Palmer, J. D., Dan, T., Wang, Y., Werner-Wasik, M., Glass, J., Kim, L., Bar Ad, V., Bhamidipati, D., Evans, J. J., Judy, K., Farrell, C. J., & Andrews, D. W. (2018). Salvage fractionated stereotactic re-irradiation (FSRT) for patients with recurrent high grade gliomas progressed after bevacizumab treatment. Journal of neuro-oncology, 137(1), 171–177. https://doi.org/10.1007/s11060-017-2709-0
Disciplines
Medicine and Health Sciences
PubMedID
29235052
Department(s)
Department of Surgery
Document Type
Article